Overview
Portfolio
More
Biostar Capital
Charlevoix, United States
Focus on transformative medical technologies with deep clinical and industry expertise to drive impactful patient outcomes.
Portfolio
12+
Employees
10+
Founded
2005
AUM
≈ $286.0M
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
United States
Fund details
Funds
Fund V
Vintage 2023 • $130.3M
Sources
Biostar Capital
Focus on transformative medical technologies with deep clinical and industry expertise to drive impactful patient outcomes.
Portfolio
12+
Employees
10+
Founded
2005
AUM
≈ $286.0M
Funds
Fund V · Vintage 2023 • $130.3M
Stages
No stages listed
Industries
No industries listedGeographic scope
United States
Sources
Showing 5 of 5 matched portfolio companies
Amplitude Vascular Systems has developed Pulse IVL™, an intravascular lithotripsy system that utilizes high-frequency pulsatile pressure waves to fracture arterial calcium and restore blood flow in patients with severely calcified arterial disease. This technology enhances deliverability and efficiency, providing healthcare providers with a reliable tool to improve patient outcomes in vascular treatments.
Funding: $45.2M
Rough estimate of the amount of funding raised
Funding: $45.2M
Rough estimate of the amount of funding raised
The startup develops pulsed electric technology that utilizes microbursts of energy delivered via catheter to disrupt cardiac cells. This approach enhances the efficacy of cardiac ablation treatments while minimizing unintended consequences associated with traditional methods.
Funding: $40.9M
Rough estimate of the amount of funding raised
Funding: $40.9M
Rough estimate of the amount of funding raised
Nectero Medical is developing the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System, which delivers a proprietary mixture directly to mid-sized abdominal aortic aneurysms to stabilize their growth and reduce the risk of rupture. This treatment aims to minimize the need for major surgical interventions, allowing patients to maintain a normal lifespan without facing the complications associated with traditional endovascular repair or open surgery.
Funding: $123.5M
Rough estimate of the amount of funding raised
Funding: $123.5M
Rough estimate of the amount of funding raised
The startup manufactures treatment devices for dry eye disease that stimulate the trigeminal parasympathetic pathway to enhance tear film production. This technology enables healthcare professionals to effectively manage chronic dry eye conditions in patients.
Funding: $8.2M
Rough estimate of the amount of funding raised
Funding: $8.2M
Rough estimate of the amount of funding raised
Senseonics offers the Eversense implantable continuous glucose monitoring system, embedding a small sensor under the skin to provide real‑time glucose readings for up to 365 days (or 180 days) via a rechargeable Bluetooth transmitter and companion mobile app. The platform removes the need for daily sensor changes, minimizes adhesive‑related skin irritation, and delivers clinically calibrated data with HIPAA‑compliant cloud storage for clinician access.
100+
10K+Approximate amount of employees
Funding: $35.0M
Rough estimate of the amount of funding raised
Funding: $35.0M
Rough estimate of the amount of funding raised
Showing 7 of 7 unmatched portfolio companies